SCHEMBL3965575

SCHEMBL3965575

COC(=O)c1cccc2cc(C)oc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 1/20 0.48
ALDH1A1 P00352 3/20 0.48
KDM4E B2RXH2 3/20 0.48
HPGD P15428 2/20 0.48
LMNA P02545 2/20 0.47
TSHR P16473 1/20 0.47
MAOA P21397 2/20 0.46
MAOB P27338 1/20 0.46
MRGPRX1 Q96LB2 1/20 0.44
SLC6A2 P23975 1/20 0.44
SLC6A4 P31645 1/20 0.44
SLC6A3 Q01959 1/20 0.44
STING1 Q86WV6 2/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
ATM Q13315 2/20 0.43
HSD17B10 Q99714 2/20 0.42
CFTR P13569 1/20 0.42
POLB P06746 2/20 0.42
PLIN1 O60240 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29784445 0.88 STING1 (0.47) CRBNALDH1A1KDM4EHPGDLMNA
SCHEMBL28190109 0.83 ALDH1A1 (0.47) ALDH1A1KDM4EHPGDLMNATSHR
SCHEMBL29784428 0.82 MAOA (0.44) ALDH1A1KDM4EHPGDMAOAMAOB
SCHEMBL3306573 0.81 MAOA (0.50) CRBNALDH1A1KDM4EHPGDLMNA
SCHEMBL14397250 0.81 KDM4E (0.46) ALDH1A1KDM4EHPGDLMNATSHR
SCHEMBL17711004 0.81 LMNA (0.49) ALDH1A1KDM4EHPGDLMNATSHR
SCHEMBL28258201 0.81 CRBN (0.54) CRBNALDH1A1KDM4EHPGDMAOA
SCHEMBL17710794 0.80 LMNA (0.48) ALDH1A1KDM4EHPGDLMNATSHR
SCHEMBL8907104 0.80 ALDH1A1 (0.44) ALDH1A1KDM4EHPGDLMNATSHR
SCHEMBL19857573 0.80 LCK (0.50) CRBNALDH1A1KDM4EHPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240216378-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF NOVARTIS AG (CH) 2024-07-04 US disclosed
US-20240216378-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF NOVARTIS AG (CH) 2024-07-04 US disclosed
US-20240216378-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF NOVARTIS AG (CH) 2024-07-04 US disclosed
US-20240109899-A1 BENZOFURAN COMPOUNDS AS STING AGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2024-04-04 US disclosed
US-11931363-B2 Triazolopyrimidine compounds and uses thereof NOVARTIS AG (CH) 2024-03-19 US disclosed
US-20230033320-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH (CN) 2023-02-02 US disclosed
US-20230033320-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH (CN) 2023-02-02 US disclosed
WO-2022169921-A1 BENZOFURAN COMPOUNDS AS STING AGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2022-08-11 WO disclosed
US-11207325-B2 Triazolopyrimidine compounds and uses thereof NOVARTIS AG (CH) 2021-12-28 US disclosed
US-11207325-B2 Triazolopyrimidine compounds and uses thereof NOVARTIS AG (CH) 2021-12-28 US disclosed
WO-2016103155-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF NOVARTIS AG (CH) 2016-06-30 WO disclosed
US-20160176882-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF NOVARTIS AG (CH) 2016-06-23 US disclosed
US-20160176882-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF NOVARTIS AG (CH) 2016-06-23 US disclosed
US-20160176882-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF NOVARTIS AG (CH) 2016-06-23 US disclosed
US-7557103-B2 Imidazopyridazine compounds ELI LILLY AND COMPANY (US) 2009-07-07 US disclosed
US-20080153828-A1 Imidazopyridazine Compounds ELI LILLY AND COMPANY 2008-06-26 US disclosed
EP-1879896-A1 IMIDAZOPYRIDAZINE COMPOUNDS ELI LILLY AND COMPANY (US) 2008-01-23 EP disclosed
WO-2006107784-A1 IMIDAZOPYRIDAZINE COMPOUNDS ELI LILLY AND COMPANY (US) 2006-10-12 WO disclosed
US-4829067-A INHIBITORS OF REFLECTIVE CONTRACTION OF BLADDER TANABE SEIYAKU CO., LTD. (JP) 1989-05-09 US disclosed
EP-0270342-A2 A benzo-furan (or -thiophene) derivative and processes for preparing the same Tanabe Seiyaku Co., Ltd. (JP) 1988-06-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11931363-B2 Triazolopyrimidine compounds and uses thereof EZH2, DOT1L, EED CRBN 182/4885ALDH1A1 529/4885KDM4E 146/4885
US-11207325-B2 Triazolopyrimidine compounds and uses thereof EZH2, DOT1L, EED CRBN 182/4885ALDH1A1 529/4885KDM4E 146/4885
US-20080153828-A1 Imidazopyridazine Compounds CRHR1, CRH, CRHR2 CRBN 524/4885ALDH1A1 1479/4885KDM4E 4385/4885
US-20240109899-A1 BENZOFURAN COMPOUNDS AS STING AGONISTS STING1, MAVS, IRF3 CRBN 4294/4885ALDH1A1 3028/4885KDM4E 2249/4885
US-20240216378-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF EZH2, DOT1L, EED CRBN 182/4885ALDH1A1 529/4885KDM4E 146/4885
US-20160176882-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF EZH2, DOT1L, EED CRBN 182/4885ALDH1A1 529/4885KDM4E 146/4885
US-20230033320-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF EZH2, DOT1L, EED CRBN 182/4885ALDH1A1 529/4885KDM4E 146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.